Cerenome
Cerenome's revenue fell 10.5% to $5 million in fiscal 2025. Its operating margin was −293.5%, down from −252.3% a year earlier. Free cash flow was −$21 million. The diluted share count rose 910.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Cerenome does
Cerenome, which filed this annual report under its former name, Plus Therapeutics, is a Houston, Texas, healthcare company working on tests and radiation drugs for cancers of the brain and spinal cord. Its subsidiary CNSide Diagnostics sells the CNSide test, a laboratory test of spinal fluid that looks for tumor cells that have spread to the central nervous system in patients with carcinomas and melanomas. It relaunched the test in August 2025, and national agreements with UnitedHealthcare and Humana give it access to more than 67 million covered lives.
Its main drug candidate, rhenium (186Re) obisbemeda, puts a radioactive substance inside tiny fat particles and delivers it through a catheter straight into a brain tumor, to give a high dose of radiation in a single treatment while sparing healthy tissue. It is in clinical trials for recurrent glioblastoma, cancer that has spread to the lining of the brain and spine, and children's brain cancers. A second candidate is meant to treat liver cancers through an injection into an artery.
The company has no approved drugs. Its revenue so far is mainly grant money: it recognized $5.2 million in 2025 from a Texas cancer research grant of up to $17.6 million, and it also has US government awards for its trials.
Its biggest risks, as it describes them
- Continued losses and a need for substantial new funding, which raise substantial doubt about its ability to continue as a going concern.
- Losing its Nasdaq listing if it cannot meet the exchange's minimum stockholders' equity requirement.
- Clinical trials may fail, take longer than planned, or not lead to approval of its drug candidates.
- Its reliance on government grants and awards, which come with conditions and depend on continued funding.
- Doctors and insurers may not accept or pay for its test and treatments.
Income statement
Cerenome lost money in fiscal 2025: a net loss of $22 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 18 | 18 | 9 | 4 | 13 |
| Debt incl. finance leases | 7 | 5 | — | — | — |
| Net debt (negative means net cash) | −12 | −13 | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.6x | 0.8x | — | — | — |
| Interest coverage | −13.4x | −27.7x | −33.7x | −82.1x | −27.9x |
| Current ratio | 3.4x | 1.8x | 0.9x | 0.3x | 1.2x |
| Quick ratio | 3.4x | 1.8x | 0.9x | 0.3x | 1.2x |
Cash flow
Projections
Project Cerenome's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Cerenome reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | −165.2% | −410.3% |
| Altman Z'' | −146.04 | −268.21 | −107.82 |
| Accruals ratio | −2.6% | −26.9% | −14.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Pass | Pass |
| F-score | — | — | — |
Compare
Put Cerenome side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Cerenome | FY25 | −10.5% | −293.5% | −399.8% | — | — | — | |
| DBV Technologies | FY25 | 35.8% | −2,609.2% | −2,159.6% | — | — | — | Compare |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
| Prime Medicine | FY25 | 55.3% | −4,498.1% | −3,607.4% | — | — | — | Compare |
| Ocugen | FY25 | 8.8% | −1,425.7% | −1,295.0% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 5 | 3 | 4 | — | — | — | — | 5 | 6 | 5 |
| Revenue growth | −3.8% | −42.2% | 36.5% | — | — | — | — | — | 18.5% | −10.5% |
| Gross profit | 2 | 0 | 2 | — | — | — | — | — | — | — |
| Research and development | 16 | 12 | 6 | 5 | 3 | 5 | 10 | 10 | 11 | 8 |
| Operating income | −20 | −21 | −9 | −4 | −10 | −12 | −20 | −13 | −15 | −15 |
| Net income | −22 | −23 | −13 | −11 | −8 | −13 | −20 | −13 | −13 | −22 |
| Diluted EPS (US$) | −9,600.00 | −6,172.50 | −1,304.70 | −124.05 | −27.90 | −16.65 | −11.58 | −4.24 | −2.34 | −0.29 |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 8 | 78 |
| Cash flow | ||||||||||
| Cash from operations | −20 | −18 | −12 | −6 | −8 | −10 | −13 | −13 | −11 | −21 |
| Capital expenditure | 0 | 0 | 0 | 0 | — | — | — | 0 | 0 | 0 |
| Free cash flow | −20 | −18 | −12 | −6 | — | — | — | −13 | −11 | −21 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | — | 10 | 5 | 18 | 8 | 18 | 18 | 9 | 4 | 13 |
| Debt incl. finance leases | 18 | 14 | 14 | 11 | 6 | 7 | 5 | — | — | — |
| Total assets | 35 | 32 | 24 | 23 | 12 | 22 | 24 | 11 | 7 | 16 |
| Total liabilities | 24 | 19 | 19 | 22 | 9 | 11 | 17 | 13 | 16 | 12 |
| Shareholders' equity | 11 | 13 | 5 | 1 | 3 | 11 | 6 | −1 | −9 | 4 |
| Margins and ratios | ||||||||||
| Gross margin | 41.7% | 5.4% | 68.7% | — | — | — | — | — | — | — |
| Operating margin | −423.2% | −769.2% | −238.7% | — | — | — | — | −271.1% | −252.3% | −293.5% |
| Net margin | −473.5% | −843.7% | −344.2% | — | — | — | — | −271.0% | −222.8% | −429.4% |
| Free cash flow margin | −421.0% | −685.1% | −329.8% | — | — | — | — | −264.8% | −183.7% | −399.8% |
| Rule of 40 (growth + FCF margin) | −424.7% | −727.4% | −293.3% | — | — | — | — | — | −165.2% | −410.3% |
| Return on capital | — | — | −44.3% | −65.4% | — | — | — | — | — | — |
| Return on equity | −190.1% | −189.2% | −138.6% | −341.0% | −393.3% | −193.2% | −234.7% | −522.5% | — | — |
| Return on assets | −61.0% | −68.5% | −45.4% | −46.1% | −46.6% | −78.6% | −88.4% | −75.5% | −144.0% | −195.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |